For Immediate Release WAIVER OF LISTING RULE 10.1 GRANTED MELBOURNE, Australia, 22 September 2026: Dimerix Limited (ASX:DXB, “Dimerix” or “the Company”), a clinical-stage biopharmaceutical company developing kidney disease treatments, advises that a waiver of Listing Rule 10.1 has been...
Waiver of Listing Rule 10.1 Granted
Filed with ASX · · 4 pages · English
Release
In the deck
Story so far
Earlier from Dimerix
- Dimerix Presents at E&P Healthcare Conference 2026
- Dimerix DMX-652 Granted Mexican Composition of Matter Patent
- Dimerix Investor Presentation
- S&P DJI Announces September 2026 Quarterly Rebalance
- Dimerix secures a$34 million non-dilutive facility to fund key clinical milestones
Later from Dimerix
- Dimerix Presents at ASX SMIDcaps Conference 2026
- Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
- Notification of 2026 Annual General Meeting Date
- Notification regarding unquoted securities - DXB
- First Patient Reaches Four Years in DMX-200 Clinical Program
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix